Page last updated: 2024-08-26

sr141716 and Dyslipidemia

sr141716 has been researched along with Dyslipidemia in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (75.00)29.6817
2010's5 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berbée, JF; Boon, MR; Guigas, B; Havekes, LM; Jukema, JW; Kooijman, S; Lombès, M; Meijer, OC; Pelgrom, LR; Rensen, PC; Sips, HC; Tamsma, JT; van Aggele, RC; van Dam, AD; van den Hoek, AM; Visseren, CA1
Deedwania, P1
Manzato, E; Marchiori, M; Zambon, A1
Alméras, N; Boka, G; Després, JP; Lemieux, I; Ross, R1
Taskinen, MR1
Odegaard, K; Persson, U; Willis, M1
Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES1
Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A1
Degrace, P; Demizieux, L; Djaouti, L; Gaba, L; Gresti, J; Jourdan, T; Vergès, B1
Chen, D; Liu, X; Shi, Y; Zhang, W1
Després, JP; Golay, A; Sjöström, L1
Yanovski, SZ1
Vinik, AI1
Majumdar, S; Padwal, R1
Boyd, ST; Fremming, BA1
Scheen, AJ; Van Gaal, LF2
Anthenelli, RM1
Watson, KE1
Després, JP; Mancia, G; Pi-Sunyer, X; Ruilope, LM; Scheen, A; Van Gaal, L; Zanchetti, A1

Reviews

5 review(s) available for sr141716 and Dyslipidemia

ArticleYear
The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
    International journal of cardiology, 2009, Jan-24, Volume: 131, Issue:3

    Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Dyslipidemias; Endocannabinoids; Humans; Insulin Resistance; Lipid Metabolism; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Signal Transduction

2009
The metabolic basis of atherogenic dyslipidemia.
    Clinical cornerstone, 2005, Volume: 7, Issue:2-3

    Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drugs, Investigational; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thiazolidinediones

2005
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
    Revue medicale de Liege, 2007, Volume: 62, Issue:2

    Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss

2007
Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
    Reviews in cardiovascular medicine, 2007, Volume: 8 Suppl 4

    Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dyslipidemias; Exercise; Humans; Insulin Resistance; Life Style; Lipids; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; Treatment Outcome; Weight Loss

2007
[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].
    Revue medicale de Liege, 2008, Volume: 63, Issue:1

    Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Piperidines; Pyrazoles; Rimonabant

2008

Trials

6 trial(s) available for sr141716 and Dyslipidemia

ArticleYear
Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:3

    Topics: Adiponectin; Adiposity; Adult; Anti-Obesity Agents; Apolipoproteins; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Cholesterol, HDL; Double-Blind Method; Dyslipidemias; Female; Humans; Insulin; Intra-Abdominal Fat; Lipoproteins, LDL; Liver; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triglycerides

2009
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
    Journal of cardiovascular pharmacology and therapeutics, 2009, Volume: 14, Issue:4

    Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant

2009
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
    Angiology, 2010, Volume: 61, Issue:4

    Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss

2010
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    The New England journal of medicine, 2005, Nov-17, Volume: 353, Issue:20

    Topics: Adiponectin; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Cannabinoid Receptor Antagonists; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Humans; Insulin; Leptin; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Triglycerides; Weight Loss

2005
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
    Revue medicale de Liege, 2007, Volume: 62, Issue:2

    Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss

2007
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
    Journal of hypertension, 2008, Volume: 26, Issue:2

    Topics: Adult; Blood Pressure; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss

2008

Other Studies

10 other study(ies) available for sr141716 and Dyslipidemia

ArticleYear
Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014, Volume: 28, Issue:12

    Topics: 3T3-L1 Cells; Absorptiometry, Photon; Adipose Tissue, Brown; Animals; Base Sequence; DNA Primers; Dyslipidemias; Mice; Mice, Transgenic; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant

2014
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
    Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1

    Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Meta-Analysis as Topic; Obesity; Piperidines; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Sex Factors

2008
ADAGIO-Lipids gives promises but faces the setbacks.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:3

    Topics: Adiponectin; Adiposity; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Humans; Insulin; Intra-Abdominal Fat; Lipids; Liver; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Treatment Outcome

2009
A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2010, Volume: 11, Issue:2

    Topics: Body Mass Index; Comorbidity; Cost-Benefit Analysis; Decision Making, Organizational; Drug Prescriptions; Dyslipidemias; Economics, Pharmaceutical; Humans; Insurance, Pharmaceutical Services; Obesity; Piperidines; Pyrazoles; Reimbursement Mechanisms; Rimonabant; State Medicine; Sweden

2010
Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:3

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Carbohydrate Metabolism; Cholesterol; Disease Models, Animal; Dyslipidemias; Fatty Liver; Gene Expression Regulation; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; Oxygen Consumption; Piperidines; Protein Kinases; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Tissue Culture Techniques

2012
Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Adiposity; AMP-Activated Protein Kinases; Animals; Diet; Dyslipidemias; Energy Metabolism; Enzyme Activation; Gene Silencing; Gene Targeting; Glucose Intolerance; Hyperinsulinism; Hyperphagia; Hypothalamus; Mice; Mice, Inbred C57BL; Obesity; Phosphorylation; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Rimonabant; Weight Loss

2012
Pharmacotherapy for obesity--promise and uncertainty.
    The New England journal of medicine, 2005, Nov-17, Volume: 353, Issue:20

    Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Cyclobutanes; Dyslipidemias; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss

2005
Metabolic risk factors, drugs, and obesity.
    The New England journal of medicine, 2006, Mar-02, Volume: 354, Issue:9

    Topics: Anti-Obesity Agents; Cardiovascular Diseases; Dyslipidemias; Glucose Intolerance; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss

2006
Update on rimonabant--a selective cannabinoid CB1 antagonist.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:5

    Topics: Cardiovascular Diseases; Dyslipidemias; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors

2006
A call to action: new treatment options provide even more reasons to intervene in tobacco dependence.
    Nature clinical practice. Cardiovascular medicine, 2007, Volume: 4, Issue:9

    Topics: Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Obesity; Piperidines; Prevalence; Pyrazoles; Quinoxalines; Rimonabant; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline

2007